🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

CSL (ASX:CSL) breaks ground on $1.5bn Kankakee plasma plant expansion, betting patented Horizon 2 technology can widen its immunoglobulin lead

CSL (ASX:CSL) breaks ground on a $1.5B Kankakee plasma plant expansion using patented Horizon 2 yield tech. Read the full strategic analysis.
CSL Limited commits $1.5B to Kankakee as plasma therapies carry group earnings burden
CSL Limited commits $1.5B to Kankakee as plasma therapies carry group earnings burden. Image courtesy of CSL//PRNewswire.